MXPA02010346A - Formulacion que tiene actividad de movilizacion. - Google Patents

Formulacion que tiene actividad de movilizacion.

Info

Publication number
MXPA02010346A
MXPA02010346A MXPA02010346A MXPA02010346A MXPA02010346A MX PA02010346 A MXPA02010346 A MX PA02010346A MX PA02010346 A MXPA02010346 A MX PA02010346A MX PA02010346 A MXPA02010346 A MX PA02010346A MX PA02010346 A MXPA02010346 A MX PA02010346A
Authority
MX
Mexico
Prior art keywords
formulation
mobilising
activity
mobilising activity
haematopoietic
Prior art date
Application number
MXPA02010346A
Other languages
English (en)
Inventor
Carmelo Carlo Stella
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa filed Critical Gentium Spa
Publication of MXPA02010346A publication Critical patent/MXPA02010346A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona una descripcion de un metodo para incrementar la cantidad de celulas troncales y celulas progenitoras en la sangre periferica de un mamifero; el metodo esta caracterizado por la administracion de defibrotida en combinacion o en proximidad temporal con al menos un factor hematopoyetico (preferentemente G-CSF) que tiene la capacidad de movilizar progenitores hematopoyeticos.
MXPA02010346A 2000-04-18 2001-04-10 Formulacion que tiene actividad de movilizacion. MXPA02010346A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00830293A EP1147777A1 (en) 2000-04-18 2000-04-18 Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
PCT/EP2001/004105 WO2001078761A2 (en) 2000-04-18 2001-04-10 Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors

Publications (1)

Publication Number Publication Date
MXPA02010346A true MXPA02010346A (es) 2004-09-06

Family

ID=8175292

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02010346A MXPA02010346A (es) 2000-04-18 2001-04-10 Formulacion que tiene actividad de movilizacion.

Country Status (31)

Country Link
US (1) US20040131588A1 (es)
EP (3) EP1147777A1 (es)
JP (1) JP5205668B2 (es)
KR (1) KR100849491B1 (es)
CN (1) CN1183962C (es)
AT (2) ATE310532T1 (es)
AU (2) AU5832201A (es)
BG (1) BG107203A (es)
CA (1) CA2406179C (es)
CY (1) CY1104971T1 (es)
CZ (1) CZ20023426A3 (es)
DE (2) DE60140015D1 (es)
DK (2) DK1276497T3 (es)
EE (1) EE200200596A (es)
ES (2) ES2252227T3 (es)
HR (1) HRP20020835A2 (es)
HU (1) HUP0300560A3 (es)
IL (1) IL152328A (es)
IS (1) IS2171B (es)
MX (1) MXPA02010346A (es)
NO (1) NO20024988L (es)
NZ (1) NZ522016A (es)
PL (1) PL358100A1 (es)
PT (1) PT1621207E (es)
RO (1) RO121006B1 (es)
RU (1) RU2248216C2 (es)
SI (1) SI21079B (es)
SK (1) SK14892002A3 (es)
UA (1) UA73566C2 (es)
WO (1) WO2001078761A2 (es)
ZA (1) ZA200208413B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
EP1656156A2 (en) * 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilization of hematopoietic cells
EP1656451A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Chimeric peptides for the regulation of gtpases
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
RU2376985C1 (ru) * 2008-07-17 2009-12-27 Владислав Николаевич Ласкавый Средство для активации стволовых клеток
AU2010363814B2 (en) 2010-11-12 2016-05-19 Gentium S.R.L. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD).
AU2012383169B2 (en) 2012-06-22 2017-12-21 Gentium S.R.L. Euglobulin-based method for determining the biological activity of defibrotide
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
CN106567694A (zh) * 2016-11-14 2017-04-19 北京国泰通源技术有限公司 智能控水短节
CN110352246A (zh) * 2018-01-12 2019-10-18 赛尔美格公司 产生细胞囊和细胞囊管的方法
KR20220071274A (ko) 2019-11-13 2022-05-31 후지필름 가부시키가이샤 가식 필름, 성형물, 및 전자 디바이스

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) * 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1043823B (it) * 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
IT1206341B (it) 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
IT1223322B (it) * 1987-10-23 1990-09-19 Crinos Industria Farmaco Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso
JP2907447B2 (ja) * 1988-08-24 1999-06-21 中外製薬株式会社 抗血栓剤
IT1231509B (it) * 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
JP3021906B2 (ja) * 1992-01-28 2000-03-15 松下電器産業株式会社 電動調理機
JPH08127539A (ja) * 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
US5856444A (en) * 1994-11-30 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Thrombocytopoiesis stimulating factor
CA2260014A1 (en) * 1996-07-10 1998-01-15 Meiji Milk Products Co., Ltd. Novel use of mk family as hematopoietic factor
AU1705599A (en) * 1997-11-26 1999-06-15 Allegheny University Of The Health Sciences Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
US6573372B2 (en) * 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of

Also Published As

Publication number Publication date
IS6581A (is) 2002-10-14
CA2406179A1 (en) 2001-10-25
PL358100A1 (en) 2004-08-09
CN1434719A (zh) 2003-08-06
CA2406179C (en) 2012-03-27
JP2004500437A (ja) 2004-01-08
NO20024988D0 (no) 2002-10-16
JP5205668B2 (ja) 2013-06-05
ES2335776T3 (es) 2010-04-05
DE60115222T2 (de) 2006-08-10
EP1621207A2 (en) 2006-02-01
HUP0300560A2 (hu) 2003-06-28
RU2248216C2 (ru) 2005-03-20
IL152328A0 (en) 2003-05-29
ES2252227T3 (es) 2006-05-16
EP1276497A2 (en) 2003-01-22
CZ20023426A3 (cs) 2003-05-14
CY1104971T1 (el) 2010-03-03
RO121006B1 (ro) 2006-11-30
EP1621207B1 (en) 2009-09-23
WO2001078761A3 (en) 2002-01-24
CN1183962C (zh) 2005-01-12
SI21079A (sl) 2003-06-30
SK14892002A3 (sk) 2003-06-03
EP1147777A1 (en) 2001-10-24
DK1276497T3 (da) 2006-03-27
HUP0300560A3 (en) 2005-07-28
PT1621207E (pt) 2009-12-28
AU5832201A (en) 2001-10-30
WO2001078761A2 (en) 2001-10-25
DE60115222D1 (de) 2005-12-29
EP1621207A3 (en) 2006-11-22
SI21079B (sl) 2006-08-31
UA73566C2 (en) 2005-08-15
AU2001258322B2 (en) 2006-03-16
EP1276497B1 (en) 2005-11-23
RU2002130719A (ru) 2004-03-27
ATE310532T1 (de) 2005-12-15
BG107203A (bg) 2003-05-30
DE60140015D1 (de) 2009-11-05
NZ522016A (en) 2004-10-29
EE200200596A (et) 2004-04-15
ZA200208413B (en) 2003-10-17
IL152328A (en) 2009-12-24
ATE443524T1 (de) 2009-10-15
HRP20020835A2 (en) 2005-10-31
IS2171B (is) 2006-11-15
KR100849491B1 (ko) 2008-07-31
DK1621207T3 (da) 2010-02-01
KR20030010603A (ko) 2003-02-05
NO20024988L (no) 2002-12-02
US20040131588A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
TW200505900A (en) Muscarinic agonists
WO2000030622A3 (de) Verwendung von dialkylfumaraten zur behandlung von host-versus-graft reaktionen und von autoimmunerkrankungen
MXPA02010346A (es) Formulacion que tiene actividad de movilizacion.
MY125539A (en) Generation of therapeutic microfoams
MXPA02003809A (es) Articulo absorbente desechable con estructura de contencion.
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
WO2001089536A3 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
TWI256309B (en) New formulation of mirtazapine
YU79802A (sh) Formulacija sa aktivnošću mobilizacije
EP1123100A4 (en) MEMORY IMPROVEMENT BY ADMINISTRATION OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION AND 3-BETA-ESTERS THEREOF
IL127851A0 (en) Inhibition of TNF activity
WO2000064421A3 (en) Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
NZ506406A (en) Compositions comprising Mycobacterium phlei DNA and methods for its use in the treatment of bladder cancer
EP0340933A3 (en) Heparin-containing formulations
WO2001032154A3 (de) Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation
Kim et al. Synergistic Cooperation Between Human Chorionic Gonadotropin and rIFN-Υ for Induction of Nitric Oxide Synthesis
ES2086518T3 (es) Compuesto farmaceutico con accion cicatrizante.
UA28031C2 (uk) Лікарська форма похідних 5- нітроімідазолу, фармацевтична композиція для лікування паразитарних та інфекційних захворювань шлунково-кишкового тракту, гастрозахищені мікрогранули похідних 5-нітроімідазолу, мікрогранули поkідних 5-нітроімідазолу з пролонгов
AU7370798A (en) Compositions and methods of therapy for igf-i-responsive conditions
UA30444A (uk) Спосіб лікування ювенільної маткової кровотечі
UA1032U (uk) Ректопростатоскоп
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
ES2165788B1 (es) Empleo de la levadura de cerveza en la elaboracion de un medicamento para el tratamiento del sindrome x fragil.

Legal Events

Date Code Title Description
FG Grant or registration